KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.

Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey

Acta Orthop 92(4) 493-499

PMID33977825
PMCIDPMC8382018
DOI10.1080/17453674.2021.1922161
发表日期2021-05-12
入排依据:The record describes a Phase III randomized clinical trial of a drug (pexidartinib) for tenosynovial giant cell tumor (oncology). However, the primary/key efficacy endpoints reported are patient-reported outcomes (physical function and stiffness), not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint.
摘要

摘要

Background and purpose - The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not recommended. Here, we detail the effect of pexidartinib on patient-reported physical function and stiffness in ENLIVEN.Patients and methods - This was a planned analysis of patient-reported outcome data from ENLIVEN, a double-blinded, randomized phase 3 trial of adults with symptomatic, advanced TGCT treated with pexidartinib or placebo. Physical function was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function (PF), and worst stiffness was assessed using a numerical rating scale (NRS). A mixed model for repeated measures was used to compare changes in PROMIS-PF and worst stiffness NRS scores from baseline to week 25 between treatment groups. Response rates for the PROMIS-PF and worst stiffness NRS at week 25 were calculated based on threshold estimates from reliable change index and anchor-based methods.Results - Between baseline and week 25, greater improvements in physical function and stiffness were experienced by patients receiving pexidartinib than patients receiving placebo (change in PROMIS-PF = 4.1 [95% confidence interval (CI) 1.8-6.3] vs. -0.9 [CI -3.0 to 1.2]; change in worst stiffness NRS = -2.5 [CI -3.0 to -1.9] vs. -0.3 [CI -0.9 to 0.3]). Patients receiving pexidartinib had higher response rates than patients receiving placebo for meaningful improvements in physical function and stiffness. Improvements were sustained after 50 weeks of pexidartinib treatment.Interpretation - Pexidartinib treatment provided sustained, meaningful improvements in physical function and stiffness for patients with symptomatic, advanced TGCT.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。